Evaluating Quality of Life and Adherence With mCRC Treatment Options

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Marwan Fakih, MD

Medical experts discuss the impact of third-line therapies (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on patient quality of life and share insights on patient adherence to these treatments.

EP: 1.Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

EP: 2.Real-World Impact of SUNLIGHT Outcomes in mCRC

EP: 3.Fruquintinib in mCRC: Key Insights From FRESCO-2

EP: 4.Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

EP: 5.Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

EP: 6.Guiding Patients Through Third-Line mCRC Therapy Decisions

EP: 7.Navigating Toxicity: Comparing Third-Line mCRC Therapies

Now Viewing

EP: 8.Evaluating Quality of Life and Adherence With mCRC Treatment Options

EP: 9.Integrating Support Services and Caregiver Roles in mCRC Care

EP: 10.mCRC Treatment Access: IRA Cost Cap Impact and Final Insights

Video content above is prompted by the following:

What has been your experience with the impact of these third-line therapy options (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on a patient’s quality of life?
What insights can you share related to patient adherence with third-line therapies in metastatic colorectal cancer?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!